• 1
    Hall M. Haemophilia complicated by an acquired circulating anticoagulant: a report of three cases. Brit J Haemat 1961; 7: 3408.
  • 2
    Roberts HR, Scales MB, Madison JT, Webster WP, Penick GD. A clinical and experimental study of acquired inhibitors to factor VIII. Blood 1965; 26: 80518.
  • 3
    Green D. Suppression of an antibody to FVIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 3817.
  • 4
    Nilsson IM, Hedner U, Björlin G. Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Ann Int Med 1973; 78: 915.
  • 5
    Nilsson IM, Hedner U, Holmberg L. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide. Acta Med Scand 1974; 195: 6572.
  • 6
    Nilsson IM, Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors. Scand J Haematol 1976; 16: 36982.
  • 7
    Edson R, McArthur JR, Branda RF, McCollough JJ, Chou SN. Successful management of a subdural hematoma in a haemophiliac with an anti-factor VIII antibody. Blood 1973; 41: 11322.
  • 8
    Hedner U, Nilsson IM. Induced tolerance in hemophilia patients with antibodies against IX:C. Acta Med Scand 1983; 214: 1917.
  • 9
    Kasper CK. Thromboembolic complications. Thromb Diath Haemorrh 1975; 33: 6404.
  • 10
    Blatt PM, Lundblad RL, Kingdon HS, McLean G, Roberts HR. Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 1974; 81: 766.
  • 11
    Fekete LF, Holst SL, Peetoom F, DE Veber LL. “Auto”factor IX concentrate: a new therapeutic approach to treatment of haemophilia A patients with inhibitors. XIV Congresso Internacional de Hamatologia, São Paulo, Brasil 26-21 de Jul, 1972. Abstr #295.
  • 12
    Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 1647.
  • 13
    Cash JD, Dalton RG, Middleton S, Smith JK. Studies on the thrombogenicity of Scottish factor IX concentrates in dogs. Thromb Diath Haemorrh 1975; 33: 6329.
  • 14
    Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 61731.
  • 15
    Hedner U, Nilsson IM, Bergentz S-E. Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thromb Haemost 1976; 35: 38695.
  • 16
    Hedner U, Nilsson IM, Bergentz S-E. Studies on thrombogenic activites in two prothrombin complex concentrates. Thromb Haemost 1979; 42: 102232.
  • 17
    Godal HC, Rygh M, Laake K. Progressive inactivation of purified factor VII heparin and antithrombin III. Thromb Res 1974; 5: 7735.
  • 18
    Østerud B, Berre Å, Otnæss A-B, Bjørklid E, Prydz H. Activation of the coagulation factor VII by tissue thromboplastin and calcium. Biochemistry 1972; 11: 28537.
  • 19
    Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh Suppl 1965; 17: 3544.
  • 20
    Penner JA, Kelly PE. Management of patients with factor VIII or IX inhibitors. Sem Thromb Hemost 1975; 1: 38699.
  • 21
    Kisiel W. Recollections on the discovery of factor VIIa as a novel therapeutic agent for haemophiliacs with inhibtors. J Thromb Haemost 2009; 7: 10536.
  • 22
    Seligsohn U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 82837.
  • 23
    Wallmark A, Ljung R, Nilsson IM et al. Polymorphism of normal factor IX detected by mouse monoclonal antibodies. Proc Natl Acad Sci USA 1985; 11: 383943.
  • 24
    Hedner U. In: Mariani G, Russo MA, Mandelli F eds. Activated Prothrombin Complex Concentrates. Managing Hemophilia with Factor VIII inhibitor. New York, NY, USA: Praeger Publishers, 1982.
  • 25
    Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two haemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 183741.
  • 26
    Hedner U, Bjoern S, Bernvil SS, Tengborn L, Stigendahl L. Clinical experience with human plasma-derived factor VIIa in patients with haemophilia A and high-titer inhibition. Haemostasis 1989; 19: 33543.
  • 27
    Foster D, Davie EW. Characterization of a cDNA coding for human protein C. Proc Natl Acad Sci USA 1984; 81: 476670.
  • 28
    Hagen FS, Fray CL, O′Hara P et al. Characterization of a cDNA coding for human factor VII. Proc Natl Acad Sci USA 1986; 83: 24126.
  • 29
    Thim L, Bjoern S, Christensen M et al. Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry 1988; 27: 778593.
  • 30
    Hedner U, Schulman S, Alberts KA et al. Successful use of rFVIIa in a patient with hemophilia A subjected to synovectomy. Lancet 1988; 2: 1193.
  • 31
    Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia, haemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA 1989; 86: 13826.
  • 32
    Hedner U, Lund-Hansen T, Winther D. Comparison of the effect of factor VII prepared from human plasma (pVIIa) and recombinant VIIa (rVIIa) in vitro and in rabbits. Thromb Haemost 1987; 58: p 270. Abstract #989 XIth Int Congr Thromb Haemostas, Brussels, 1987.
  • 33
    Hedner U. Factor VIIa in treatment of haemophilia. Blood Coag Fibrinolysis 1990; 1: 30717.
  • 34
    Monroe DM, Roberts HR, Hoffman M. Platelet procoagulant complex assembly in a tissue factor-initiated system. Br J Haematol 1994; 88: 36471.
  • 35
    Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 6427.
  • 36
    Roberts HR, Monroe DM, Hoffman M. Molecular biology and biochemistry oft he coagulation factors and pathways of haemostasis. In: Coller BS, Kipps TJ, Seligsohn U eds. Williams Hematology. 6th edn, Chapter 112. New York, NY: McGraw-Hill Companies Inc, 2001: 140934.